Merck's boceprevir improves cure rates in two pivotal hepatitis C trials
This article was originally published in Scrip
Executive Summary
Merck & Co's investigational hepatitis C protease inhibitor, boceprevir, has significantly improved cure rates of those with chronic hepatitis C virus (HCV) genotype 1, when added to standard of care, in its first two Phase III trials in treatment-naïve and treatment-failure patients.